改善病情抗风湿药与类风湿关节炎患者新发间质性肺病风险:系统综述与荟萃分析
该系统综述与荟萃分析纳入40篇文献、486465例类风湿关节炎患者和3928例新发间质性肺病结局,评估改善病情抗风湿药与新发间质性肺病的关联。随机对照试验的汇总分析未显示任何特定改善病情抗风湿药与新发间质性肺病风险存在统计学显著关联;观察性数据显示甲氨蝶呤和托法替布可能具有潜在保护作用,但研究可能存在偏倚,需进一步前瞻性研究。
要点
- 随机对照试验汇总分析未显示任何特定改善病情抗风湿药与新发间质性肺病风险存在统计学显著差异。
- 7项观察性研究汇总显示,使用甲氨蝶呤者新发间质性肺病的OR为0.49(95%CI 0.32至0.76,p<0.001)。
- 单項观察性研究中,托法替布使用者相比肿瘤坏死因子抑制剂使用者新发间质性肺病的OR为0.36(95%CI 0.15至0.87,p=0.024)。
核心结论
- 观察性数据提示任何改善病情抗风湿药均未增加新发类风湿关节炎相关间质性肺病风险,甲氨蝶呤和托法替布可能具有潜在保护作用。
- 随机对照试验中未显示任何特定改善病情抗风湿药与新发类风湿关节炎相关间质性肺病存在关联。
- 这些研究可能易受偏倚影响。
- 需要进一步设计良好的前瞻性研究才能就改善病情抗风湿药与类风湿关节炎相关间质性肺病风险之间的潜在关系得出明确结论。
研究设计与样本
- 系统文献综述与荟萃分析,检索PubMed、Embase、Web of Science和Cochrane Library自建库至2023年11月。
- 纳入随机对照试验、观察性研究和上市后监测研究,研究对象为成人类风湿关节炎患者,比较感兴趣的改善病情抗风湿药与安慰剂、无改善病情抗风湿药或其他改善病情抗风湿药,结局为新发间质性肺病。
- 共纳入40篇文献,涵盖486465例类风湿关节炎患者和3928例新发间质性肺病结局;其中24项随机对照试验、4项前瞻性队列研究、9项回顾性队列研究、2项病例对照研究和1项上市后监测研究。
- 对质量充分的研究采用Mantel-Haenszel法进行荟萃分析,计算比值比(OR)和95%置信区间(95%CI)。
主要发现
- 随机对照试验的汇总分析显示,在所有比较中,任何特定改善病情抗风湿药与新发间质性肺病风险均无统计学显著差异。
- 最大的随机对照试验(Oral Surveillance试验)中,托法替布组(n=2911)与肿瘤坏死因子抑制剂组(n=1451)相比,新发间质性肺病无关联(OR 0.94,95%CI 0.52至1.69,p=0.828)。
- 7项观察性研究中,使用甲氨蝶呤者相比未使用甲氨蝶呤者,新发间质性肺病的汇总OR为0.49(95%CI 0.32至0.76,p<0.001)。
- 单項观察性研究中,托法替布使用者相比肿瘤坏死因子抑制剂使用者,新发间质性肺病的OR为0.36(95%CI 0.15至0.87,p=0.024)。
关键数值与推荐
- 随机对照试验汇总分析:任何特定改善病情抗风湿药在所有比较中与新发间质性肺病风险均无统计学显著差异。
- Oral Surveillance试验:托法替布(n=2911)vs 肿瘤坏死因子抑制剂(n=1451),新发间质性肺病OR 0.94(95%CI 0.52至1.69,p=0.828)。
- 7项观察性研究汇总:使用甲氨蝶呤 vs 未使用甲氨蝶呤,新发间质性肺病OR 0.49(95%CI 0.32至0.76,p<0.001)。
- 单項观察性研究:托法替布 vs 肿瘤坏死因子抑制剂,新发间质性肺病OR 0.36(95%CI 0.15至0.87,p=0.024)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些研究可能易受偏倚影响。
- 需要进一步设计良好的前瞻性研究才能就改善病情抗风湿药与类风湿关节炎相关间质性肺病风险之间的潜在关系得出明确结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association of disease-modifying antirheumatic drugs (DMARDs) and risk of incident interstitial lung disease (ILD) among patients with rheumatoid arthritis (RA) using a systematic literature review and meta-analysis. METHODS: We performed a systematic literature review and meta-analysis of studies examining the association of DMARDs with incident RA-ILD. PubMed, Embase, Web of Science, and Cochrane Library were searched from inception to November 2023 for randomized controlled trials (RCTs), observational studies, and post-marketing surveillance studies that investigated adults with RA and compared DMARDs of interest with placebo, no DMARDs, or other DMARDs. The outcome was incident ILD. We summarized the literature on DMARDs and incident RA-ILD risk. Among studies with sufficient quality, we performed meta-analyses to obtain odds ratios (OR) and 95 % confidence intervals (95 %CI) using the Mantel-Haenszel method. RESULTS: Among 3,612 studies, we identified a total of 40 papers that encompassed 486,465 patients with RA and 3,928 incident ILD outcomes that were included in the final systematic review and meta-analysis. Among the studies, 24 were RCTs, 4 were prospective cohort studies, 9 were retrospective cohort studies, 2 were case-control studies, and 1 was a post-marketing surveillance study. The pooled analysis from RCTs revealed no statistically significant difference in the odds of ILD development for any specific DMARD across all comparisons examined. The largest identified RCT (Oral Surveillance trial) of tofacitinib (n = 2,911) vs. tumor necrosis factor inhibitor (TNFi, n = 1,451) found no relationship with incident ILD (OR 0.94, 95 %CI 0.52 to 1.69, p = 0.828). In 7 observational studies, the use of methotrexate (MTX) yielded a pooled OR for ILD of 0.49 (95 %CI 0.32 to 0.76, p < 0.001) compared to those not using MTX. In a single observational study, tofacitinib users had an OR for ILD of 0.36 (95 %CI 0.15 to 0.87, p = 0.024) compared to TNFi users. CONCLUSION: Observational data suggest no increased risk for any DMARD for incident RA-ILD risk, and perhaps a potential protective role of MTX and tofacitinib. However, these studies may be susceptible to bias, and no specific DMARD showed associations with incident RA-ILD in RCTs. Further well-designed prospective studies are warranted for definitive conclusions on the potential relationship between DMARDs and RA-ILD risk.
引用
- Zhang Q, McDermott GC, Juge PA, et al. Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2024. PMID: 39413452. doi:10.1016/j.semarthrit.2024.152561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。